To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women

NCT02862171 PHASE3 COMPLETED Results posted

A follow-on, open label trial to assess continued safety of and adherence to the Dapivirine(25mg) vaginal ring-004 in healthy, HIV-negative women

Details

Lead sponsor	International Partnership for Microbicides, Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	941
Start date	Tue Jul 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• HIV Prevention

Interventions

• Dapivirine Vaginal Ring-004

Countries

South Africa, Uganda